HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From Ipsen SA

Ipsen Gets Ahead Of The Qirv in Cholangitis

Iqirvo gains accelerated approval, but Gilead’s seladelpar is probably only two months behind.

Approvals Commercial

Ipsen Dealmaking Heats Up With Marengo Cold Tumor Collaboration

The France-based mid-sized drugmaker has solidified its pipeline through several external pacts in the past few years and its dealmaking is showing no signs of slowing down.

Business Strategies Oncology

BIO Notebook: Dealing With Rejection, Worrying About March-In Rights, And More

Insights from the first day of the international convention in San Diego also includes interviews on Alzheimer’s investments, dealmaking for mid-sized companies and reflections on the virtues of lean thinking.

BIO Deals

BIO Notebook: Dealing With Rejection, Worrying About March-In Rights, And More

Insights from the first day of the international convention in San Diego also includes interviews on Alzheimer’s investments, dealmaking for mid-sized companies and reflections on the virtues of lean thinking.

BIO Deals
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • OTC, Consumer
    • Specialty Pharmaceuticals
  • Other Names / Subsidiaries
    • Clementia Pharmaceuticals, Inc.
    • Epizyme, Inc.
    • Ipsen Bioscience, Inc.
    • Sterix
    • Tercica, Inc.
    • Syntaxin Ltd.
    • OctreoPharm Sciences GmbH
    • Octagen Corporation
UsernamePublicRestriction

Register